Cytek Biosciences, Inc. filed a current report on Form 8-K on August 24, 2026, disclosing a jury verdict returned on August 21, 2026, in a patent infringement action brought by Beckman Coulter, Inc. in the United States District Court for the District of Delaware.
Key Highlights
- Jury verdict: A jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc.
- Three claims decided in company's favor: The jury found noninfringement and invalidity as to three of the four asserted patent claims.
- One claim infringed under doctrine of equivalents: The jury found no literal infringement on the remaining claim but found infringement under the doctrine of equivalents.
- Past damages awarded: The jury awarded $20 million in lost profits and $36.11 million in royalties.
- Post-verdict motions planned: Cytek Biosciences stated it intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.
- Further remedies possible: The company disclosed it may also pursue other available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit.
Beckman Coulter Patent Action: Verdict Details and Cytek's Planned Response
According to the filing, Cytek Biosciences (NASDAQ:CTKB) announced on August 21, 2026, that a jury reached its verdict in the patent infringement case initiated by Beckman Coulter, Inc. in the United States District Court for the District of Delaware. The company reported that the jury found in Cytek's favor on three of the four asserted patent claims, specifically determining noninfringement and invalidity with respect to each of those three claims.
On the remaining claim, the filing states the jury found no literal infringement but nonetheless found infringement under the doctrine of equivalents. As a result, the jury awarded past damages consisting of $20 million in lost profits and $36.11 million in royalties, according to the filing. Cytek disclosed that it intends to pursue post-verdict motions to challenge both the infringement finding under the doctrine of equivalents and the associated damages award.
The filing also noted that the company may pursue other available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit. The filing contains forward-looking statements regarding these intentions, which the company stated are subject to risks and uncertainties, including the outcome of any post-trial motions, appeals, and further legal proceedings, as well as the possibility of additional costs, injunctive relief, and ongoing royalty obligations as determined by the court. The company noted these forward-looking statements are subject to its cautionary language and are made as of the filing date, with no obligation to update them except as required by law.
What Was Disclosed
Cytek Biosciences disclosed a jury verdict in a Beckman Coulter patent infringement action, with the jury finding infringement on one claim under the doctrine of equivalents and awarding $20 million in lost profits and $36.11 million in royalties as past damages, while finding in Cytek's favor on three other claims.



Please wait processing your request...